📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-16 19:42
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Ambani Orgochem amends EGM notice for Rs 43.93 Cr warrant issue following NSE review
Ambani Orgochem has issued a corrigendum to its October 26, 2026 EGM notice following observations from the NSE and a board decision to exclude one proposed allottee. The proposed preferential issue of convertible warrants is now revised slightly lower to 43,92,500 warrants (from 43,95,000) at Rs 100 per warrant, aiming to raise up to Rs 43.93 crore. The fundraise equals approximately 70% of the company's net worth of Rs 63 crore and 10% of TTM revenue. Proceeds will fund working capital (Rs 20.00 crore), business expansion/premises acquisition (Rs 13.00 crore), and general corporate purposes (Rs 10.93 crore).
Confidence: HIGH
What changedExcluded one allottee (2,500 warrants) and clarified valuation and floor price calculation details per NSE observations.
Why it mattersThe Rs 43.93 crore equity-linked infusion provides crucial capital relative to its Rs 63 crore net worth, supporting expansion and reducing leverage (current D/E is 1.24).
Revised fundraise amount: Rs 43.925 CrIssue size vs Net Worth: ~69.7%Issue price per warrant: Rs 100Floor price determined by valuer: Rs 61.13Warrants offered to Promoter Rakesh Shah: 30,00,000
📅 Short termVoting at the EGM on October 26, 2026, followed by the receipt of initial 25% warrant subscription monies (Rs 10.98 crore).
📈 Long termSignificant equity dilution over 18 months as warrants are converted, though capital infusion can help finance Dahej expansion and relieve working capital pressures.
⚠ Risk flags
- Equity dilution of ~33% upon full conversion of warrants
- 75% of funds are contingent upon warrants being exercised within 18 months
Key Highlights
Preferential warrant issue trimmed by 2,500 warrants to 43,92,500 warrants, reducing total size to Rs 43.925 crore
Issue price fixed at Rs 100 per warrant against an independent valuer floor price of Rs 61.13
Proceeds allocated to working capital (Rs 20.00 crore), business expansion (Rs 13.00 crore), and general corporate purposes (Rs 10.925 crore)
Promoter Rakesh Hasmukhlal Shah is the anchor subscriber with 30,00,000 warrants (22.54% fully diluted stake)
25% (Rs 10.98 crore) payable upfront, with the remaining 75% payable upon warrant exercise within 18 months
👀 What to Watch
Track shareholder voting results from the EGM scheduled on October 26, 2026, followed by formal in-principle and listing approvals from NSE.
H1 FY27 Net Profit Jumps to ₹3.41 Cr; Revenue Up 55% YoY at ₹171.22 Cr
Ambani Orgochem reported standalone revenue from operations of ₹171.22 Cr for the half year ended September 30, 2026, up 55% YoY from ₹110.56 Cr. Standalone net profit surged to ₹3.41 Cr compared to ₹0.20 Cr in H1 FY26, supported by higher operating scale and an extraordinary item of ₹67.87 lakhs. The auditor issued an Emphasis of Matter regarding an insurance claim receivable of ₹817.87 lakhs for loss of profit from the Dahej factory fire, which is pending final settlement. Additionally, the company converted 12.60 lakh warrants into equity and redeemed ₹4.55 Cr of preference share capital.
Confidence: HIGH
What changedAmbani Orgochem declared its unaudited H1 FY27 results, reporting substantial YoY revenue and profit growth while adjusting insurance receivables and capital structure.
Why it mattersThe company shows an operational turnaround with expanding revenues and profitability following recovery from the earlier Dahej fire incident, though working capital remains intensive.
H1 FY27 Total Income: ₹17,122.12 lakhsH1 FY27 Net Profit: ₹340.87 lakhsLoss of Profit Insurance Claim: ₹817.87 lakhsPreference Shares Redeemed: ₹4,55,23,200H1 Revenue vs TTM Revenue: ~39.1%
📅 Short termMarket reaction may be positive due to strong top-line and bottom-line expansion compared to the low base of H1 FY26.
📈 Long termStructural improvement depends on sustained profitability at the Dahej facility, full clearance of insurance receivables, and debt reduction.
⚠ Risk flags
- Auditor emphasis of matter on unfinalized insurance claim receivable of ₹817.87 lakhs
- Negative cash flow from operations before working capital adjustments was offset, but working capital changes absorbed ₹9.31 Cr
- High finance costs of ₹5.28 Cr in H1 FY27 relative to operating profit
Key Highlights
Standalone total income from operations rose 54.8% YoY to ₹171.22 Cr in H1 FY27 from ₹110.56 Cr in H1 FY26
Net profit after tax stood at ₹3.41 Cr versus ₹0.20 Cr in the year-ago half year
Insurance loss-of-profit eligible claim assessed by surveyor at ₹817.87 lakhs and recognized as receivable
Converted 12,60,000 warrants into equity shares upon receiving the balance 75% issue price
Redeemed 45,52,320 preference shares amounting to ₹4.55 Cr during the period
👀 What to Watch
Monitor the actual receipt and final settlement of the ₹817.87 lakh insurance claim over the next six months, along with operating margins and working capital intensity.
Ambani Orgochem to Raise ₹43.95 Cr via Convertible Warrants; EGM on Oct 26
Ambani Orgochem has issued a notice for an Extraordinary General Meeting (EGM) on October 26, 2026, to approve the preferential issue of up to 43,95,000 convertible share warrants at an issue price of ₹100 each. The total fundraise amounts to ₹43.95 crore, which represents approximately 78.5% of its current net worth of ₹56 crore. Of the total warrants, 30.1 lakh warrants are proposed to be allocated to the promoter group (primarily Rakesh Hasmukhlal Shah), and the remaining 13.85 lakh to non-promoter public investors. The company is also reclassifying ₹7 crore of unissued preference share capital into equity share capital to facilitate the expansion of equity base.
Confidence: HIGH
What changedAmbani Orgochem has sought shareholder approval to reclassify its share capital and issue 43.95 lakh convertible warrants at ₹100 each on a preferential basis.
Why it mattersThe ₹43.95 crore capital infusion significantly strengthens the company's equity base (net worth ₹56 cr) and provides liquidity to deleverage (debt ₹72 cr) or fund the ongoing Dahej Phase 2 expansion.
Total warrants offered: 43,95,000Issue price per warrant: Rs. 100/-Total fundraise value: ₹43.95 crFundraise vs Net Worth: ~78.5%Promoter allocation: 30,10,000 warrantsEGM Date: 26th October, 2026
📅 Short termShare price sentiment will likely be influenced by the warrant pricing (₹100) and substantial promoter participation heading into the EGM on October 26, 2026.
📈 Long termFull conversion of warrants over the statutory 18-month period will expand the equity base, potentially reduce the 1.29 D/E ratio, and support long-term capacity utilization at the Dahej unit.
⚠ Risk flags
- Equity dilution of existing minority shareholders upon conversion of 43.95 lakh warrants
- Execution and ramp-up risks at Dahej Phase 2 expansion project
Key Highlights
Proposed issuance of up to 43,95,000 convertible warrants at ₹100 per warrant (including ₹90 premium), raising ₹43.95 crore
Fundraise represents ~78.5% of net worth (₹56 cr) and ~10.0% of TTM revenue (₹438 cr)
Promoter group to be allotted 30,10,000 warrants (68.5% of issue), signaling promoter financial commitment
Reclassification of 70,00,000 unissued preference shares (₹7 cr) into equity shares to expand authorised equity capital to ₹20 cr
Minimum 25% upfront payment required at warrant allotment, with remaining 75% payable upon exercise
👀 What to Watch
Track shareholder voting outcomes at the EGM on October 26, 2026, followed by the formal allotment of warrants and the timeline for capital deployment toward ongoing Dahej Phase 2 expansion.
Ambani Orgochem Board Approves Preferential Issue of Up to 43.95 Lakh Convertible Warrants
Ambani Orgochem has approved a preferential issue of up to 43,95,000 convertible warrants, each convertible into one equity share within 18 months, subject to shareholder approval at an EGM on October 26, 2026. Promoter Rakesh Harsukhlal Shah is slated to receive 30,00,000 warrants, which will increase his personal stake from 48.94% to 55.32% on a fully diluted basis. The issue price will be determined per SEBI ICDR regulations and is not yet disclosed. The board also approved the adoption of a new set of Articles of Association aligned with Table F of the Companies Act, 2013.
Confidence: HIGH
What changedThe board approved issuing 43.95 lakh warrants to promoters and non-promoters, along with adopting a new Articles of Association.
Why it mattersThe preferential issue infuses fresh capital into the business and signals promoter commitment as the primary promoter expands his stake, though it will dilute non-participating shareholders.
Total Warrants Proposed: 43,95,000Warrants to Promoter Rakesh Shah: 30,00,000Rakesh Shah Post-Dilution Stake: 55.32%Conversion Period: 18 monthsEGM Date: October 26, 2026
📅 Short termShareholders will vote on the preferential issuance at the EGM on October 26, 2026; price determination details will be critical.
📈 Long termEquity capital will support the company's balance sheet (current debt of Rs 72 Cr vs net worth of Rs 56 Cr) and potential ongoing expansions like Dahej Phase 2.
⚠ Risk flags
- Equity dilution for existing minority shareholders
- Pricing details and exact fundraise amount not yet disclosed
Key Highlights
Issue of up to 43,95,000 convertible warrants into equity shares on a preferential basis
Promoter Rakesh Harsukhlal Shah to be allotted 30,00,000 warrants, increasing holding from 48.94% to 55.32%
Warrants convertible into equity shares within an 18-month tenure from allotment
EGM scheduled on October 26, 2026, to seek shareholder approval
👀 What to Watch
Track the upcoming EGM voting outcome on October 26, 2026, and look out for the exact pricing disclosure per SEBI pricing norms to evaluate dilution and capital inflow.
Ambani Orgochem Outlines Capacity Expansions in Salicylic Acid and Acrylic Coatings
Ambani Orgochem released an investor presentation detailing significant operational capacity expansions. In its acrylic coatings and adhesives business, capacity is expanding 2.25x from ~2,000 tonnes/month to ~4,500 tonnes/month at Tarapur. The company is also quadrupling its in-house Salicylic Acid capacity from ~50 tonnes/month to ~200 tonnes/month to support downstream value-added derivatives. Currently, the company holds an aggregate capacity of over 50,000 MT/year across 4 manufacturing facilities.
Confidence: HIGH
What changedAmbani Orgochem submitted its September 2026 corporate investor presentation detailing ongoing capacity additions and product pipelines.
Why it mattersThe company operates at thin TTM net margins (PAT Rs 0 Cr on Rs 438 Cr revenue); scaling high-margin downstream salicylates and expanding acrylic emulsion volume is key to operational leverage.
Current Aggregate Capacity: 50,000+ MT/YearAcrylic Coatings Capacity Target: ~4,500 T/month (from ~2,000 T/month)Salicylic Acid Capacity Target: ~200 T/month (from ~50 T/month)Downstream Salicylate Molecules in Development: 12+
📅 Short termInformational disclosure offering clarity on operating metrics, though it contains no immediate earnings shock or unexpected order announcement.
📈 Long termSuccessful commercialization of the Tarapur doubling and Dahej expansions could enhance revenue scale beyond the current TTM run-rate of Rs 438 Cr and improve operating profitability.
⚠ Risk flags
- Execution delays in Dahej and Tarapur expansions
- High leverage with D/E of 1.29 and debt of Rs 72 Cr vs net worth of Rs 56 Cr
- Stiff industry competition limiting pricing flexibility
Key Highlights
Acrylic coatings and adhesives capacity expanding 2.25x from ~2,000 T/month to ~4,500 T/month at Tarapur
In-house Salicylic Acid capacity quadrupling from ~50 T/month to ~200 T/month
Aggregate manufacturing capacity exceeds 50,000 MT/year across 4 facilities in Tarapur and Dahej
Developing 5 additional peroxide molecules and 2 critical raw materials in-house for backward integration
👀 What to Watch
Track the commercial operational dates and capital expenditure spending for the Tarapur and Dahej expansions, along with subsequent margin improvement from value-added salicylates.
